X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CPI-444 (ciforadenant) is an investigational small molecule, oral, checkpoint inhibitor designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of adenosine in the tumor microenvironment to the A2A receptor.
Lead Product(s): Ciforadenant,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: CPI-444
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
Angel adds Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 and Corvus’ BTK inhibitor preclinical programs to its pipeline. Strategic collaboration gives Corvus 49.7% equity stake in Angel Pharmaceuticals.
Lead Product(s): Ciforadenant,Atezolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Angel Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 05, 2020
Details:
Data is based on results from the Company’s Phase 1b/2 trial of ciforadenant in patients with advanced RCC and demonstrates the potential role of CD68+ myeloid cells, which are a downstream target of adenosine as a biomarker to further enrich for responding patients.
Lead Product(s): Ciforadenant,Atezolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
Corvus recemtly completed enrollment 25 patients with advanced refractory renal cell cancer in an amended ph 1b/2 clinical trial evaluating ciforadenant in combination with Genentech’s Tecentriq®.
Lead Product(s): Ciforadenant,Atezolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
Details:
The mCRPC arm of the study, is evaluating ciforadenant monotherapy and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody.
Lead Product(s): Ciforadenant
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
